PCSK9 monoclonal antibodies and lipoprotein apheresis for lowering lipoprotein(a): making choices in an era of RNA-based therapies

Abstract

Get full access to this article

View all access options for this article.

References

Grundy

Stone

Bailey

et al.

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol. Circulation. Epub ahead of print 10 November 2018. DOI: 10.1161/CIR.0000000000000625.

Sabatine

Giugliano

Keech

et al.

Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713–1722.

Schwartz

Steg

Szarek

et al.

Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379: 2097–2107.

Sbrana

Dal Pino

Bigazzi

et al.

Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: after PCSK-9 antibodies what else?

Eur J Prev Cardiol 2017; 24: 1528–1531.

Kaufman

Warden

Minnier

et al.

Application of PCSK9 inhibitors in practice. Circ Res 2019; 124: 32–37.

Reyes-Soffer

Pavlyha

Ngai

et al.

Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation 2017; 135: 352–362.

Watts

Chan

Somaratne

et al.

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J 2018; 39: 2577–2585.

Ooi

Watts

Chan

et al.

Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2015; 35: 2686–2693.

O’Donoghue

Fazio

Giugliano

et al.

Lipoprotein(a), PCSK9 inhibition and cardiovascular risk: insights from the FOURIER Trial. Circulation. Epub ahead of print 30 November 2018. DOI: 10.1161/CIRCULATIONAHA.118.037184.

10.

Bittner

Szarek

Aylward

et al.

Lp(a) and cardiovascular outcomes: an analysis from the ODYSSEY OUTCOMES Trial. Arterioscler Suppl 2018; 32: 24–24.

11.

Willeit

Ridker

Nestel

et al.

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet 2018; 392: 1311–1320.

12.

Watts

Boffa

. Lipoprotein(a): lodestar for future clinical trials. Lancet 2018; 392: 1281–1282.

13.

Kojima

Shida

Yokoyama

. Changes in C-reactive protein plasma levels during low-density lipoprotein apheresis. Ther Apher Dial 2003; 7: 431–434.

14.

Zenti

Altomari

Lupo

et al.

From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Eur J Prev Cardiol 2018; 25: 1843–1851.

15.

Dihazi

Koziolek

Sollner

et al.

Protein adsorption during LDL-apheresis: proteomic analysis. Nephrol Dial Transplant 2008; 23: 2925–2935.

16.

Moriarty

Parhofer

Babirak

et al.

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. Eur Heart J 2016; 37: 3588–3595.

17.

Stiekema

LCA

Stroes

ESG

Verweij

et al.

Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment. Eur Heart J. Epub ahead of print 18 December 2018. DOI: 10.1093/eurheartj/ehy862.

18.

Safarova

Ezhov

Afanasieva

et al.

Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl 2013; 14: 93–99.

19.

Pokrovsky

Afanasieva

Safarova

et al.

Specific Lp(a) apheresis: a tool to prove lipoprotein(a) atherogenicity. Atheroscler Suppl 2017; 30: 166–173.

20.

Stefanutti

Julius

Watts

et al.

Toward an international consensus-integrating lipoprotein apheresis and new lipid-lowering drugs. J Clin Lipidol 2017; 11: 858–871.

21.

Veljic

Polovina

Milinkovic

et al.

Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 inhibitors: do we have a vanquishing new strategy?

Eur J Prev Cardiol 2019; 26: 739–742.

22.

Sbrana

Dal Pino

Bigazzi

et al.

Effect of proprotein convertase subtilisin/kexin type 9 inhibitors on lipoprotein(a) still to be unravelled. Eur J Prev Cardiol. 2019; 26: 782.

23.

Tsimikas

. RNA-targeted therapeutics for lipid disorders. Curr Opin Lipidol 2018; 29: 459–466.